Relief is coming for more than 5 million Medicare beneficiaries who rely on expensive prescription medications.

The Center for Medicare and Medicaid Innovation may introduce a five-year pilot model to expand access to weight loss drugs, ...

Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.

Novo Nordisk, the Danish maker of the wildly popular Ozempic and Wegovy drugs used for weight loss, was downgraded due to ...

Earlier this year, the Centers for Medicare and Medicaid Services scrapped a previous proposal, from the Biden administration ...

UBS downgraded its rating of Novo to "neutral" from "buy" and lowered its 12-month price target to 340 Danish krone from 600 Danish krone. Copenhagen-listed shares in Novo, which have slumped by more ...

The Texas governor is threatening Democrats who don’t show up to the Capitol to vote on his gerrymandered maps.

The Justice Department is trying to distance itself from Miller and his expectations for federal agents to arrest 3,000 ...

President Trump escalated pressure on the pharmaceutical industry last week by sending letters to 17 major drug companies ...

The second-quarter earnings season for the drug and biotech sector accelerated last week and will be in full swing this week, ...

Trump administration eyes Medicare and Medicaid coverage for weight loss drugs like Wegovy and Ozempic in a five-year pilot ...

UBS has lowered its rating on Novo Nordisk (NYSE:NVO) from 'buy' to 'neutral', slashing the price target to DKK340 from ...